Drug Profile
Epoetin theta - Teva
Alternative Names: Biopoin; Eporatio; EpoTheta-Teva; RatioepoLatest Information Update: 23 May 2017
Price :
$50
*
At a glance
- Originator Ratiopharm
- Developer Teva Pharmaceutical Industries
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 23 May 2017 No recent reports on development identified - Registered for Anaemia in Iceland and Norway (SC)
- 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (IV) prior to February 2015
- 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (SC) prior to February 2015